Unicycive Therapeutics (UNCY) Asset Utilization Ratio (2023)

Unicycive Therapeutics' (UNCY) quarterly Asset Utilization Ratio came in at 0.04 in Q4 2023, up 25.84% on a QoQ basis from 0.03 in Q3 2023.

Unicycive Therapeutics (UNCY) Asset Utilization Ratio (2023) Analysis & Trends

Unicycive Therapeutics (UNCY) has 1 years of Asset Utilization Ratio data on file, last reported at 0.04 in Q4 2023.

Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.04 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 0.04 (changed N/A YoY) and the FY2023 annual result came in at 0.08, down 10.02% from the prior year.
Asset Utilization Ratio climbed to 0.04 in Q4 2023, from 0.03 in the prior quarter.
In the past five years, Asset Utilization Ratio ranged from a high of 0.06 in Q2 2023 to a low of 0.03 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.38
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.20
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.69
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.90
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.13
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.54
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.13
10	Unicycive Therapeutics	151.01 Mn	151.01 Mn	-	-

Download Data